ADVERTISEMENT
Real-World Adoption of Bevacizumab Biosimilar for Metastatic Colorectal Cancer
Findings from a recent real-world study support the adoption of bevacizumab-awwb, a bevacizumab biosimilar, for the treatment of metastatic colorectal cancer (CRC; Future Oncol. 2021; 17[36]:5119-5127. doi:10.2217/fon-2021-0588).
In this study, Whitney Rhodes, PhD, ConcertAI, Memphis, TN, and colleagues aimed to evaluate real-world use of bevacizumab-awwb for the treatment of metastatic CRC.
Using the ConcertAI oncology dataset, Dr Rhodes and colleagues identified 304 adult patients with metastatic CRC who received bevacizumab-awwb during the first year after market availability.
Among participants, 47% initiated bevacizumab-awwb as reference product naive patients and 53% received bevacizumab-awwb with prior exposure to the reference product. A total of 78% of participants received bevacizumab-awwb as first-line therapy. In those with prior exposure to the reference product, 83% were transitioned from reference product to bevacizumab-awwb in the same line without disease progression.
“In US community-based oncology practices, bevacizumab-awwb was used in treating mCRC both in new patients, primarily as first line of therapy and in existing reference product-treated patients with no intervening line of treatment,” concluded Dr Rhodes and colleagues.
“Future studies with long-term follow-up will be warranted to evaluate safety and effectiveness data of bevacizumab-awwb use in patients with metastatic CRC,” they added.
